WASHINGTON — An effort to use congressional legislation to incentivize the development of new antibiotics fell short Wednesday, despite lobbying pressure from pharmaceutical companies and medical societies.

Antibiotics are rarely moneymakers for drug makers, and yet there’s wide agreement that there’s a need for more given that some bacteria are increasingly resistant to the therapies currently on the market.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • If our senator’s aren’t going to do anything to improve life for Americans. Maybe they should at least legalize physician assisted suicide. So we can at least die with some dignity. Instead of the slow painful way they are doing to pain patients.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy